ValuePlayground
Posted - 10 minutes from now
$CC pounding the table on this extremely undervalued name with brand new 2 phase immersion cooling technology that will revolutionize data center cooling ($1.8B TAM with 25% CAGR). Hefty dividend, healthy balance sheet, nothing not to like here. $SPY $QQQ $NVDA
ValuePlayground
Posted - 21 minutes ago
$CC good follow through just starting
ValuePlayground
Posted - 19 hours ago
$CC solid close with big buys end of day. This will catch a real bid in the upcoming days that sends it back to mid 20s at least
ValuePlayground
Posted - 20 hours ago
$CC looking like a breakout over 20 is imminent on the big data center cooling news plus insider buy this morning. $SPY $QQQ
ValuePlayground
Posted - 1 day ago
$CC announced 2 phase immersion cooling refrigerant for data center cooling. https://www.3blmedia.com/news/two-phase-immersion-cooling-can-unlock-40-decreased-data-center-energy-use-and-sustainable
Big news for longs plus 10k insider buy announced. Looking for new 52 week highs soon.
KristopherMurphy
Posted - 1 day ago
$CC $CCCC LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?
ValuePlayground
Posted - 2 days ago
$CC long here for the next 6mos makes too much sense. Way over sold.
cubie
Posted - 3 days ago
@ribbey @simon58 @judgeyoung2 @Alvi722 @jenbunn @EBE_Day @Ollip @TraderRapp @tonyctl @lukenight bc $cc has lower IV than $oklo , cubie said oklo werent cheap. hence double vs quadruple on ccj
NVDAMillionaire
Posted - 3 days ago
$CC The Chemours Company (CC): Delivering Trusted Chemistry Through Disciplined Execution https://beyondspx.com/article/chemours-cc-a-diversified-chemical-giant-navigating-challenges-with-resilience
ValuePlayground
Posted - 1 week ago
$CC added leaps and 1 month out calls
JackDarwin
Posted - 2 weeks ago
$CC Nice Gap Up Formed With High Volume.
OpenOutcrier
Posted - 2 weeks ago
$CC (+7.3% pre) Chemours's stock jumps on quarterly revenue growth https://ooc.bz/l/46752
briefingcom
Posted - 2 weeks ago
Gapping up: $DERM +13.2% $GTE +7.9% $YUMC +6.5% $CC +6.5% $VKTX +4.9%
DonCorleone77
Posted - 2 weeks ago
$CC Chemours sees Q4 revenue down in the mid to high-single digits sequentially The company said, "In the Q4, TSS anticipates a sequential low-teens Net Sales decline driven by refrigerant seasonality, while expecting TSS to maintain overall double-digit year-over-year growth in Opteon Refrigerants. TSS Adjusted EBITDA is expected to decrease in the low-20% range sequentially due to refrigerant seasonality. TT expects a mid- to high-single digit sequential Net Sales decline, with seasonality driving lower volumes, as well as impacts from mix of regional sales. Adjusted EBITDA is expected to decrease between mid-to-high teens, consistent with the referenced sequentially-lower volumes and mix. APM expects a low-single digit Net Sales decline in the fourth quarter, driven by macro weakness in Advanced Materials end markets slightly offsetting increases in Performance Solutions. Adjusted EBITDA is anticipated to be broadly flat sequentially due to the favorable contribution from Performance Solutions sales and cost reduction efforts across the business. The Company anticipates a consolidated Net Sales decrease in the mid to high-single digits sequentially, with consolidated Adjusted EBITDA down in the high teens to low 20% range compared with Q3 results. Corporate Expenses, as an offset to Adjusted EBITDA, are expected to be generally in line with the Q3. Overall unrestricted cash in the Q4 is anticipated to remain generally in line with the Q3, generating a positive operating cash flow. Cash uses in the Q4 will be concentrated around planned maintenance activities and the expansion of TSS's production site at Corpus Christi, Texas. The Company expects total capex in the Q4 to be in the range of approximately $100M, due to elevated growth capital spend in TSS.
DonCorleone77
Posted - 2 weeks ago
$CC Chemours reports Q3 adjusted EPS 40c, consensus 28c Reports Q3 revenue $1.50B, consensus $1.44B. "In the Q3, we delivered strong results, meeting our Net Sales expectations and exceeding our Adjusted EBITDA expectations. We set a Net Sales record for TSS5, driven by robust 21% year-over-year growth in Opteon(TM) Refrigerants and made steady progress in APM with high single-digit year-over-year growth in our Performance Solutions portfolio. Our TT segment delivered a 23% year-over-year increase in Adjusted EBITDA amid the lingering impacts of the now resolved Altamira temporary facility closure in the Q2, underscoring our resilient and effective operational execution," said Denise Dignam, Chemours President and CEO. "We are also outlining our refreshed corporate strategy, designed to position Chemours for sustainable growth and long-term value creation, with a sharpened focus on near-term execution."
Estimize
Posted - 2 weeks ago
$CC reported - EPS and - revenue for Q3.
http://www.estimize.com/intro/cc?chart=historical&metric_name=eps&utm_content=CC&utm_medium=actual
unnconscious
Posted - 2 weeks ago
$CC always short the earnings. I'm doing it the old fashioned way this time, just shorting tons of shares (puts are pricy with the election)
chkmate102
Posted - 2 weeks ago
On the plus side, $CC and $ADM are still in business and still traded on NASDAQ
chkmate102
Posted - 2 weeks ago
$SMCI this one reminds me of $CC and $ADM when the news broke out about their book and situation.
untial
Posted - 2 weeks ago
$LYB I think it will recover ... the whole sector is bad now. look at $DOW, $CC. $LYB is still one of the best chemical company. Patience
ChessGM
Posted - 10/31/24
$CC Heads up alert! Upcoming Earnings on 11/4/2024 Bearish (2.5) The Chemours Company (CC) is currently facing significant challenges as reflected in its recent financial metrics and analyst reports. The company is expected to report a decline in earnings for Q3 2024, which is not favorable considering the broader industry context. A recent downgrade by RBC Capital, which lowered the price target from $35 to $28, underscores concerns regarding ongoing weaknesses in Europe and unplanned operational outages affecting performance. This reflects broader issues within the commodity chemicals sector, where earnings expectations have been revised downward. Chemours has been grappling with an EPS that has shown a decline over the past five years, and current P/E ratios suggest that the stock is trading at a premium compared to its industry peers, indicating potential overvaluation. Revenue forecasts are also under pressure, with anticipated declines affecting future growth prospects. While the company has a consistent dividend policy, investors should be cautious given the forecasted challenges. Looking ahead, Chemours is set to release its Q3 2024 earnings report, and expectations are low, with analysts predicting a decrease in earnings. Historical performance has shown variability, and investor sentiment is likely to be heavily influenced by this upcoming report. Analyst consensus estimates indicate a cautious outlook, and any significant deviation from expectations could lead to increased volatility in the stock price. The potential impact of these results on the stock may be exacerbated by the current economic environment, where interest rate cuts are expected to take time to benefit sectors like construction, which is crucial for Chemours' recovery. Overall, the company appears to be navigating through a challenging landscape, and investors should proceed with caution given the bearish sentiment surrounding its upcoming earnings performance. - Funds were net buyers of $CC during the previous reporting quarter. - Top 5 funds with large holdings in $CC: * Forest Avenue Capital LP $19MM. CGMRank: 56% * Balyasny Asset Management LLC $14MM. CGMRank: 64% * Sir Capital Management LP $13MM. CGMRank: 59% * D. E. Shaw & Co $7MM. CGMRank: 82% * Arga Investment Management LP $2MM. CGMRank: 83% - Last 10 days performance: -7% - Last 30 days performance: -10% - Last 90 days performance: -20% Follow ChessGM! Make your move and get timely, free earnings alerts from ChessGM. Not a financial advice.
Estimize
Posted - 10/28/24
Wall St is expecting -3.04% YoY revenue growth for $CC in Q3, up from -6.39% in Q2 [Reporting 11/04 BMO]
http://www.estimize.com/intro/cc?c
Obelix60
Posted - 10/25/24
$CCL $CC This Growth Stock Is Up 50% in 6 Months and Can Still Go Higher
One stock that's been benefiting from a more favorable outlook with respect to interest rates is Carnival Corporation (CCL -0.43%). The cruise ship operator's stock has risen more than 50% in just the past six months, but there's plenty of reason to remain bullish on this travel stock for the long haul
https://www.fool.com/investing/2024/10/24/this-growth-stock-is-up-50-in-6-months-and-can-sti/
Obelix60
Posted - 10/25/24
$CC This Growth Stock Is Up 50% in 6 Months and Can Still Go Higher
One stock that's been benefiting from a more favorable outlook with respect to interest rates is Carnival Corporation (CCL -0.43%). The cruise ship operator's stock has risen more than 50% in just the past six months, but there's plenty of reason to remain bullish on this travel stock for the long haul
https://www.fool.com/investing/2024/10/24/this-growth-stock-is-up-50-in-6-months-and-can-sti/
WeeklyTrader
Posted - 10/23/24
What’s your exit plan for $CC? RSI: 42.83% 50-day MA: $18.97 200-day MA: $24.43
Jhall41018
Posted - 1 month ago
$CC is it true there are only two manufacturers of 454B, CC and Honeywell? 90% of HVAC equipment going that way in 2 months. That’s a lot of demand for refrigerant!
WeeklyTrader
Posted - 1 month ago
Celebrate gains with $CC! RSI: 54.09% 50-day MA: $18.83 200-day MA: $24.79
Thestocktraderhubzee
Posted - 1 month ago
WATCHLIST OCT 14 2024
$COHR Needham Maintains Buy on Coherent, Raises Price Target to $120
$ARWR HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
$IVZ RBC Capital Maintains Sector Perform on Invesco, Raises Price Target to $18
$HUN RBC Capital Maintains Sector Perform on Huntsman, Raises Price Target to $24
$CC RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $28
anachartanalyst
Posted - 1 month ago
$CC
https://anachart.com/wp-content/uploads/ana_temp/1728669749_soc-img.jpg